A novel cell-penetrating peptide TAT-A1 delivers siRNA into tumor cells selectively (2013)
Sequence: YGRKKRRQRRRGWFLLTM
| Experiment Id | EXP001431 |
|---|---|
| Paper | A novel cell-penetrating peptide TAT-A1 delivers siRNA into tumor cells selectively |
| Peptide | TAT-A1 (VEGFR1-targeted TAT) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | 10 µM peptide in complexation (typical); peptide-only uptake tested 0.1–10 µM |
| Rna Concentration | 50 nM siRNA (uptake + knockdown assays) |
| Mixing Ratio | Electrostatic noncovalent complexes; typical peptide:siRNA molar ratio 30:1 (screened 10:1–40:1); peptide 10 µM with siRNA 50 nM; incubated 30 min at 37°C |
| Formulation Format | Noncovalent CPP/siRNA electrostatic complexes (aggregates/nanoparticles) |
| Formulation Components | TAT-A1 (VEGFR1-targeted TAT) + siRNA |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HUVEC (human umbilical vein endothelial cells; VEGFR1-positive) |
| Animal Model | |
| Administration Route | |
| Output Type | Uptake/internalization of 5'-FAM siRNA by flow cytometry (6 h) |
| Output Value | |
| Output Units | |
| Output Notes | FAM-siRNA uptake increased with TAT-A1:siRNA ratio and plateaued around 30:1; siRNA alone showed no uptake. |
| Toxicity Notes | |
| Curation Notes |